Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received

Background: The ProtecTtrial reported intention-to-treat analysis of menwith localised prostate cancer randomly allocated to active monitoring (AM), radical prostatectomy, and external beam radiotherapy. Objective: To report outcomes according to treatment received in men in randomised and treatment choice cohorts. Design, setting, and participants: This study focuses on secondary care. Men with clinically localised prostate cancer at one of nine UK centres were invited to participate in the treatment trial comparing AM, radical prostatectomy, and radiotherapy.

[1]  Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. , 2023, The New England journal of medicine.

[2]  T. Peters,et al.  Factors associated with trial recruitment, preferences and treatments received were elucidated in a comprehensive-cohort study. , 2019, Journal of clinical epidemiology.

[3]  F. Saad,et al.  Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer , 2018, The New England journal of medicine.

[4]  R. Pazdur,et al.  Metastasis-free Survival - A New End Point in Prostate Cancer Trials. , 2018, The New England journal of medicine.

[5]  D. Margolis,et al.  MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.

[6]  J. Sterne,et al.  Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial , 2018, JAMA.

[7]  K. Muir,et al.  The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study , 2018, BMC Medicine.

[8]  F. Saad,et al.  Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.

[9]  O. Sartor,et al.  Metastatic Prostate Cancer. , 2018, The New England journal of medicine.

[10]  T. Peters,et al.  A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial , 2017, Journal of clinical epidemiology.

[11]  J. Oxley,et al.  Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial , 2017, European urology.

[12]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[13]  M. Roobol,et al.  Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers. , 2015, European urology.

[14]  Danny Vesprini,et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Peters,et al.  Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. , 2014, The Lancet. Oncology.

[16]  A. Renshaw,et al.  Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. , 2006, The Journal of urology.

[17]  G. Guyatt,et al.  Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis , 2002, BMJ : British Medical Journal.

[18]  A. Renshaw,et al.  Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era , 2002, Cancer.

[19]  T. Peters,et al.  SCORING THE SHORT FORM ICSmaleSF QUESTIONNAIRE , 2000 .

[20]  H M Sandler,et al.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. , 2000, Urology.

[21]  A. Renshaw,et al.  Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy , 1998, Cancer.

[22]  D J Newell,et al.  Intention-to-treat analysis: implications for quantitative and qualitative research. , 1992, International journal of epidemiology.

[23]  D. Rubin.  INFERENCE AND MISSING DATA , 1975 .

[24]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.